Direct effects of dopamine on renin release were examined using static incubations and perifusions of rat renal cortical slices. Dopamine (10~5 M) significantly stimulated renin release compared with control. To determine which receptors are involved in dopamine-elicited renin release, studies were performed with specific dopamine-1 and dopamine-2 receptor agonists and antagonists, as well as with a-and 0-adrenergic antagonists. Fenoldopam, a dopamine-1 receptor agonist, dose dependently stimulated renin secretion both in static incubations and perifusions; whereas quinpirole (10~7-10~5 M), a dopamine-2 receptor agonist, was ineffective. I n recent years, it has become apparent that dopamine (DA), an endogenous catecholamine, plays an important role in physiological regulation outside the central nervous system. For example, endogenous DA may inhibit aldosterone release and increase renal sodium excretion,'-4 and variations in hypophysial portal blood DA levels may influence leutinizing hormone, folliclestimulating hormone, growth hormone, and thyroidstimulating hormone secretion and play a key role in pituitary prolactin secretion.
I
n recent years, it has become apparent that dopamine (DA), an endogenous catecholamine, plays an important role in physiological regulation outside the central nervous system. For example, endogenous DA may inhibit aldosterone release and increase renal sodium excretion,'- 4 and variations in hypophysial portal blood DA levels may influence leutinizing hormone, folliclestimulating hormone, growth hormone, and thyroidstimulating hormone secretion and play a key role in pituitary prolactin secretion. 3 -8 Since the kidney can produce DA and dopaminergic endings terminate directly on the kidney juxtaglomerular cells, it has been reported that DA may directly stimulate renin release. 9 -' 3 However, since DA activates not only two distinct peripheral dopamine-1 (DA,) and dopamine-2 (DA2) receptors, but also a-and /3-adrenergic receptors, the mechanisms of DA stimulation of renin release are not clear. 10 -' 6 When DA was injected into canine renal arteries, there was release of renin by specific dopaminergic receptor activation. 1213 Other studies of direct effects of DA on the kidney juxtaglomerular cells were interpreted to indicate that DA stimulates renin via /3-adrenergic receptor activation. 1011 The recent availability of selective DA| and DA 2 receptor agonists and antagonists prompted us to use these compounds to study the presence and subtype of DA receptors involved in juxtaglomerular cell renin secretion. Fenoldopam mesylate is a specific DA| receptor agonist. Compared with DA, this compound is four times more potent as a renal vasodilator in dogs. 17 Furthermore it has minimal a 2 -but no a,-or 0-adrenergic receptor activity. 1819 Similarly, quinpirole (LY171555) is reported to be a selective DA 2 receptor agonist in peripheral tissues. 2021 In the present studies, we examined the direct actions of fenoldopam and quinpirole (DA, and DA 2 receptor agonists) on renin secretion. In addition, we have evaluated the role of a-and
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Materials and Methods

Methods
Fenoldopam mesylate was a gift from Smith Kline and French Laboratories (Philadelphia, Pennsylvania); quinpirole hydrochloride (LY171555) was a gift from Eli Lilly and Company (Indianapolis, Indiana), and SCH 23390 maleate was a gift from Schering Corporation (Bloomfield, New Jersey). Phentolamine was obtained from Ciba Pharmaceutical Company (Summit, New Jersey). Dopamine (3-hydroxytyramine hydrochloride), isoproterenol, and DL-propranolol hydrochloride were from Sigma Chemical Company (St. Louis, Missouri), and pimozide (R,6238) was purchased from Janssen Pharmaceutica (Piscataway, New Jersey).
Male Sprague-Dawley rats (150-250 g) were decapitated, and superficial slices from the dorsal and ventral side of the kidney (0.5-mm thick) were used for static incubation and perifusion experiments (Endotronics Acusyst S Perifusion System, Marietta, Ohio), as previously described.
22
- 23 For static incubations, slices (15-30 mg) were washed with KrebsRinger bicarbonate with glucose (KRBG) medium that contained 0.01% bovine serum albumin. Slices were preincubated in a metabolic shaker, saturated with 95% O 2 -5% CO 2 at 37° C for 15 minutes and then incubated for five consecutive 15-minute incubation periods. Each slice was incubated for two 15-minute baseline periods, after which various agents were added; the response to an agent was observed for the next three 15-minute periods, thus enabling each slice to serve as its own control. The standard KRBG medium contained (mM): NaCl 120, KC1 4.7, MgSO 4 1.2, CaCl 2 2.5, KH 2 PO 4 1.2, NaHCO 3 26.8, and glucose 10, pH 7.4. For perifusions, slices were placed in culture chambers and perifused with KRBG buffer, as described previously. 24 After an initial 60-minute stabilization period, 10-minute fractions were collected. After a 30-minute baseline sampling, the agents were dissolved in 20 ml KRBG buffer and perifused over a 20-minute period. This was followed by a control KRBG buffer for a period of 30 minutes.
In experiments where DA or isoproterenol effects were studied, ascorbic acid (6xlO~4 M) was added to the KRBG medium as an antioxidant. 23 Fenoldopam, quinpirole, and SCH 23390 were dissolved in KRBG medium immediately before use. Pimozide was dissolved in a minimum volume of acetone and diluted to the required concentration in ethanol. The final concentration of ethanol in KRBG medium was 0.05%. This concentration of ethanol was also added to control incubations not exposed to test compounds and did not influence renin activity. To investigate the effects of a, /3, or DA antagonists on renin release induced by DA or fenoldopam, slices were incubated or perifused with KRBG that con- tained these antagonists for 15 minutes before administration of the agents. Renin release in the supernatant of the incubations or perifusion medium was determined by radioimmunoassay to measure the generation of angiotensin I by the method of Haber as used by one of us before.
-23
The results are expressed as the mean±SEM percent control renin release. Statistical analysis was performed using the CL INFO System. Analysis of variance with both unpaired t tests and Duncan's multiple range tests was used to assess the significance of renin release, as previously described. 23 In the studies of perifusion of kidney slices, the area under the curve was subjected to one-way analysis of variance, followed by Duncan's multiple comparison tests.
Results
Effects of Dopamine on Renin Release
In static incubations, DA at 10~7 or 10" 6 M increased renin slightly at 30 minutes (Figure 1 ), but 10" 5 M concentration significantly increased renin release compared with control slices (control 91 ±6%, DA 143±9%, p<0.001).
Effects of a-and fi-Adrenergic Blockade on Dopamine-Induced Renin Release
Since DA, at certain doses, activates both a-and 0-adrenergic receptors, we first examined the effects of adrenergic blockade on DA-induced renin release. As shown in Table 1 , in static incubations addition of the a-adrenergic blocker phentolamine (10~4 M) or the /3-adrenergic blocker propranolol (2x 10~5 M) did not alter DA (10~5 M)-induced renin release (DA 159±10%, DA+phentolamine 145±10%, or DA+propranolol 195 ±13%); whereas propranolol significantly blocked isoproterenol (a /3-adrenergic agonist)-induced renin release, /?<0.001 (Table 1) .
To fully evaluate the more definite role of DA and its mechanisms, perifusion studies were performed. Renin release in the control slices was relatively stable over the 80-minute time period (Figure 2A ). DA (10~5 M) increased renin secretion over the control slices. However, propranolol at concentrations as much as 2x 10~4 M did not significantly affect the DA-stimulated renin secretion (Figure 2A) . Whereas, in the same model propranolol (2xl0~3 M) blocked the isoproterenol (10"* M>induced renin release ( Figure 2B ).
Effects of Specific Dopamine Agonists on Renin Secretion
To determine if the action of DA to increase renin release involves a specific dopaminergic mechanism, the effects of the specific DA, receptor agonist fenoldopam and the DA 2 agonist quinpirole were studied. In static incubations fenoldopam increased renin in a dose-related manner (fenoldopam, 10"* M 117±10, p<0.02, 10" 5 M 148±14, p<0.001) and was 10 times more potent than DA in its action ( Figure 3 ). In contrast, quinpirole, a DA 2 agonist (10" 7 -10" 5 M), did not alter basal renin release.
Effects of a-and fi-Adrenergic Blockade on Fenoldopam-Induced Renin
Since DA is capable of activating adrenergic receptors, the possibility that fenoldopam, a DA, receptor agonist, may also have similar actions was investigated. In static incubations, both phentolamine (10" 4 M) and propranolol (2x 10~4 M) did not block fenoldopam-induced renin release (Table 2) . Similarly, in perifused slices the presence of pro- pranolol did not alter renin activity stimulated by fenoldopam ( Figure 4 ). In fact, both in static incubations and perifusion studies with fenoldopam, the renin stimulatory activity of slices was slightly higher in the presence of propranolol, as was seen in studies with DA (Table 1, Figure 2A ).
Effects of Specific Dopamine-1 and -2 Receptor Antagonists on Dopamine and Fenoldopam
To further characterize the specificity of dopaminergic mechanism, studies were performed with specific DA] and DA 2 receptor antagonists, SCH 23390 and pimozide, respectively.
In static incubations, SCH 23390 significantly blocked both DA and fenoldopam-induced renin secretion (DA 149±9%, DA+SCH 23390 93±4%, p<0.001; fenoldopam 142±9%, fenoldopam+SCH 23390 89±4%, /?<0.001) and was specific in its actions as it did not alter isoproterenol-induced renin release (isoproterenol 145 ±5%, isoproterenol+SCH 23390 165 ±9%) ( Table 3) . Pimozide had no effect on either DA or fenoldopam-induced renin secretion (Table 3) .
Discussion
The findings of the present study confirm earlier reports that DA is a direct renin secretagogue, 10 Figure 1 ), an observation consistent with the other reports. 10 -" Peripheral DA receptors have been classified into two subtypes. 1516 The DA! receptor is located on several blood vessels and when activated leads to vasodilation.
-
28 DA 2 receptors are located presynaptically, and stimulation of presynaptic DA 2 receptors inhibits the release of norepinephrine from the sympathetic ganglia and nerve terminals. "• 293° Since juxtaglomerular renin-secreting cells are of vascular origin and free DA is generated in the kidney, 431 we evaluated the direct role of DA, and DA 2 receptors on renin release. Fenoldopam, a selective DA! receptor agonist, mimicked the effects of DA on renin secretion. This phenomenon of increased renin activity with fenoldopam has been noted by others in in vivo studies. 32 -33 In contrast, quinpirole, a selective DA 2 receptor agonist, did not alter renin secretion.
Since DA also possesses a-and /3-adrenergic agonistic properties, we determined if adrenergic activation or a specific dopaminergic mechanism was involved in a DA-induced rise in renin release. The stimulation of renin release by DA or fenoldopam in the present study was not blocked by the a-adrenergic antagonist phentolamine or the /Jadrenergic blocker propranolol. This was seen not only in static incubations, but also in the perifusion system of renal cortical slices, which is considered more physiological. In this system, products from slices and medium are continuously washed out, and the contents of the medium are kept constant. Moreover, the perifusion system is thought to be more sensitive in detecting the effects of agents on renin secretion. With this system, propranolol, at a dose that completely blocked the isoproterenolinduced increases in renin, had no significant effect on DA or fenoldopam-induced renin release. These results suggest that DA stimulates renin release independent of the a-or /3-adrenergic system. These findings are in conflict with reports by Henry et al. trary to our results, propranolol at 2x10 * M concentrations significantly blocked DA-secreted renin release. We have no explanation for these results. We did notice, however, that in our system propranolol at 2x 10~4 M levels showed a significant agonistic effect on renin release (unpublished observations). In addition, in DA-and fenoldopam-treated groups, the presence of propranolol caused a further slight rise in renin. Other in vitro reports have similarly indicated agonistic actions of propranolol on basal renin levels. 2536 It is unclear whether this effect of propranolol is due to a nonspecific action. Propranolol has been reported to have direct actions on cell membranes and can act as a membrane stabilizing agent. 37 It is interesting to note, however, that angiotensin II-induced aldosterone inhibition by DA has also been shown not to be mediated by the activity of DA at /3-adrenergic receptors. 38 Our data importantly indicate that this stimulatory action of DA on renin is due to selective action of DA, receptors and does not involve DA 2 receptors. This is based on the following observations: 1) the DA, receptor agonist, fenoldopam, was active in inducing renin release; whereas, the DA 2 receptor agonist quinpirole was inactive; 2) the most specific DA, receptor antagonist SCH 23390 39 -40 completely antagonized the actions of both DA and fenoldopam; 3) the two different DA 2 receptor antagonists, pimozide 26 and metoclopramide 16 (unpublished observations), did not alter either DA-or fenoldopam-promoted renin release. Other investigators have similarly shown that fenoldopaminduced renin is not altered by metoclopramide. 33 These data clearly show that receptors on reninsecreting cells that respond to DA involve specific DA,-type receptors and support the findings made by earlier investigators that identified the presence of DA receptors using dopaminergic antagonists. Imbs et al 13 showed in anesthetized dogs that haloperidol, a dopaminergic blocker, but not propranolol, was effective in antagonizing the renin release. Similarly, Mizoguchi et al 12 infused DA intrarenally into conscious dogs and showed a significant increase in renin secretion that was not inhibited by propranolol, but was inhibited by two DA antagonists, sulpiride and haloperidol.
The cellular mechanisms by which DA induces its stimulatory effect on renin remain to be established. DA, receptors have been closely linked to the adenylate cyclase-cyclic adenosine monophosphate (cAMP) messenger system. 16 Whereas, in pituitary studies, DA 2 receptors have been coupled to changes in calcium inositol phosphate formation.
41
- 42 The secretion of renin is known to be under the control of both calcium and cAMP messenger systems, acting in a concerted fashion.
2243 - 43 The intracellular events elicited by activation of the specific DA, juxtaglomerular receptors need to be fully evaluated.
The physiological function of DA on the kidneyrenin-angiotensin-aldosterone system is not yet established. Dopaminergic fibers end in proximity to the juxtaglomerular apparatus, and DA receptors have been identified in the rat adrenal gland and renal glomeruli.
-
46
- 47 Furthermore, low doses of DA have a vasodilatory effect, and this effect is more pronounced in the kidney than in other organs. 1413 The mechanisms by which DA, receptors modulate renal hemodynamic changes are not fully understood. 153948 The possibility that local alterations in DA production in kidney may be responsible for physiological or pathophysiological modifications of renin-angiotensin II-aldosterone responses awaits future study.
In conclusion, our data demonstrate that DA may play a direct stimulatory role in the control of renin release by kidney juxtaglomerular cells. Although DA has effects at multiple receptor sites (i.e., at a-and j3-adrenergic as well as at DA, and DA 2 receptors), the potential renin-stimulating activity of DA appears to be restricted to specific DA, receptor activation. Evidence that specific dopamine-1 receptor activation is involved in dopamine-induced renin
